Extranodal involvement in lymphoma – A Pictorial Essay and Retrospective Analysis of 281 PET/CT studies

Document Type : Original Article

Authors

1 Nuclear Medicine and PET/CT, Tata Medical Center, New Town, Kolkata, India

2 Radiology Department,Tata Medical Center, New Town, Kolkata, India

3 Haematology Department, Tata Medical Center, New Town, Kolkata, India

Abstract

Objective(s): The aim of this study is to evaluate the role of PET-CT in identification of different patterns of extranodal involvement in Hodgkin’s disease (HD) and Non-Hodgkin’s Lymphoma (NHL) and to enlist the common sites of extranodal involvement in each histological type and compare our results with the existing literature.
Methods: In this retrospective study of 281 cases of lymphomas of various histologies, we illustrate the spectrum of PET/CT features of extranodal lymphoma (ENL) of commonly involved organs and compare our result with the literature. Result: Extranodal appearance in lymphoma is strikingly varied. Diffuse large B cell lymphoma (DLBCL) is the commonest histological subtype and gastrointestinal tract is the commonest anatomical subsite in NHL. Skeletal system is the commonest site for involvement in HD.
Conclusion: A broad spectrum of extranodal organs is involved in various subtype of lymphoma which can be depicted in PET-CT in the most appropriate manner. Familiarity with the pattern of involvement is essential for comprehensive management.

Keywords

References

  1. Paes FM, Kalkanis DG, Sideras PA, Serafini AN. FDG PET/CT of extranodal involvement in non-Hodgkin lymphoma and Hodgkin disease. Radiographics. 2010; 30:269-91.
  2. Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Mester U. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.. Radiol Clin N Am. 2007; 45: 697-709.
  3. Gurney KA, Cartwright RA. Increasing incidence and descriptive epidemiology of extranodal non- Hodgkin lymphoma in parts of England and Wales. Haematol J. 2002; 3:95-104.
  4. Groves FD, Linet MS, Travis LB, Devesa SS. Cancer survillence series: non Hodgkin’s lymphoma incidence by histologic subtype in United States from 1978 through 1995. J Natl Cancer Institute. 2000; 92: 1240-51.
  5. Glass AG, Karnell LH, Menck HR. The National Cancer Data Base report on non Hodgkin’s lymphoma. Cancer. 1997;80:2311-20.
  6. Zucca E, Conconi A, Cavelli F. Treatment of extranodal lymphomas. Best Pract Res Clin Haematol. 2002; 15:533-47.
  7. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?. Eur J Nucl Med. 2000;27:1564-78.
  8. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emmission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clinical Oncol. 2007;25:571-8.
  9. Zucca E, Roggero E, Bertoni F, Conconi A, Cavalli F. Primary extranodal non-Hodgkin's lymphomas. Part 2: Head and neck, central nervous system and other less common sites. Ann Oncol. 1999;10:1023-33.
  10. Byun BH, Na II, Cheon GJ, Kang HJ, Kim KM, Lee SS, et al. Clinincal significance of 18F-FDG uptake by the primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study. Ann Nucl Med. 2008; 22:645-51.
  11. King AD, Lei KIK, Ahuja AT. MRI of primary non-Hodgkin’s lymphoma of the palatine tonsil. BJR. 2001; 74: 226-9.
  12. King AD, Lei KI, Richards PS, Ahuja AT. Non-Hodgkin’s lymphoma of the nasopharynx:CT and MR imaging. Clin Radiol. 2003;58:621-5.
  13. Karantanis D, Subramaniam RM, Peller PJ, Lowe VJ, Durski JM, Collins DA, et al. The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma. Clinical Lymphoma Myeloma. 2008;8:94-9. 
  14. Karantanis D, Bogsrud TV, Wiseman GA, Mullan BP, Subramaniam RM, Nathan MA, et al. Clinical significance of diffusely increased 18F-FDG  uptake in thyroid gland. J Nucl Med. 2007;48:896-901.
  15. Agale SV, D’ Costa GF, Hastak MS, Shedge RK. Primary non-Hodgkin's lymphoma of the salivary gland|: A spectrum of lymphoepithelial sialadenitis, low-grade B-cell lymphoma of the mucosa associated lymphoid tissue with transformation to high grade lymphoma. Indian J Pathol Microbiol. 2010;53:364-7.
  16. Nieuwenhuizen L, Verzijlbergen FJ, Wiltink E, Grutters JC, Biesma DH. A possible role of 18F-FDG positron emmission tomography scanning in the early detection of Rituximab- induced pneumonitis in patients with non-Hodgkin's lymphoma. Haematologica. 2008; 93:1267-9.
  17. Sarah JV, Rodney HR. Reticuloendothelial Disorders: In: Andy Adam, editor. Grainger & Alison’s Diagnostic Radiology A textbook of Medical Imaging. 5th  ed.  Philadelphia: Elsavier Limited; 2003. P:1733-58.
  18. Weijs LE, Arsos G, Baarslag HJ, Wittebol S, deKlerk JM. Pericardial involvement in a non-Hodgkin lymphoma patient: coregistered FDG PET and CT imaging. Eur Heart J. 2007;28:2698.
  19. Buchmann I, Wandt H, Wahl A, Reske SN. FDG PET for imaging pericardial manifestation of Hodgkin lymphoma. Clin Nucl Med. 2003;28:760-1.
  20. Guermazi A, Brice P, Kerviler ED, Ferme C, Hennequin C, Meignin V, et al. Extranodal Hodgkin disease: spectrum of disease 1. Radiographics. 2001;21:161-79.
  21. Salvagno L, Sorarù M, Busetto M, Puccetti C, Sava C, Endrizzi L, et al. Gastric non-Hodgkin’s lymphoma: analysis of 252 patient from a multicenter study. Tumori. 1999;85:113-21
  22. Dodd GD. Lymphoma of the hollow abdominal viscera. Radiol Clin North Am. 1990; 28:771-83.
  23. Radan L, Fischer D, Bar-Shalom R, Dann EJ, Epelbaum R, Haim N, et al. FDG avidity and PET/CT pattern in primary gastric lymphoma. Eur J Nucl Med Mol Imaging. 2008;35:1424-30.
  24. Sam JW, Levine MS, Farner MC, Schuster SJ, Alavi A. Detection of small bowel involvement by Mantle cell lymphoma on F-18 FDG positron emission tomography. Clin Nucl Med. 2002;27:330-3.
  25. Rini JN, Leonidas JC, Tomas MB, Palestro CJ. 18F-FDG PET versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med. 2003;44:1072-74.
  26. Ezzat A, Jamshed A, Khafaga Y, Rahal M, Linjawi T, Martin J, et al. Primary pancreatic non-Hodgkin’s lymphomas. J Clin Gastroenterol. 1996;23:109-12.
  27. Moog F, Kotzerke J, ReskeSN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med. 1999;40:1407-13.
  28. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Merkle E, Frickhofen N, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206:475-81.
  29. Evan-Sapir E. Imaging of malignant bone involvement by morphologic, scintgraphic and hybrid modalities. J Nucl Med. 2005;46:1356-67.
  30. Sugawara Y, Zasadny KR, Kison PV, Baker LH, Wahl RL. Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. J Nucl Med. 1999;40:1456-62.
  31. Samuel LM, White J, Lessells AM, Roddie H, Matheson LM. Primary non-Hodgkins lymphoma of muscle. Clin Oncol. 1999;11:49-51.

Files

Share

How to cite

Statistics